Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535078 | 1.00 | NR1H2 (0.35) | NR1H2NR1H3HSD11B1GPR119MEN1 | |
| SCHEMBL16041277 | 1.00 | NR1H2 (0.35) | NR1H2NR1H3HSD11B1GPR119MEN1 | |
| SCHEMBL29751596 | 0.88 | NR1H2 (0.35) | NR1H2NR1H3HSD11B1MEN1KMT2A | |
| SCHEMBL30595968 | 0.87 | NR1H2 (0.33) | NR1H2NR1H3HSD11B1GPR119MEN1 | |
| SCHEMBL27240520 | 0.87 | DRD2 (0.33) | — | |
| SCHEMBL17628950 | 0.87 | DRD2 (0.33) | — | |
| SCHEMBL17628812 | 0.87 | DRD2 (0.33) | — | |
| SCHEMBL38653342 | 0.84 | NR1H2 (0.35) | NR1H2NR1H3HSD11B1STSRORC | |
| SCHEMBL24700389 | 0.84 | NR1H2 (0.34) | NR1H2NR1H3HSD11B1GPR119MEN1 | |
| SCHEMBL4758394 | 0.83 | GAA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000692-A1 | Substituted N-(Pyridin-2-yl)Acetamide Derivatives as CDK12/13 Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2026-01-01 | — | — | US | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119562812-A | Substituted N- (pyridin-2-yl) acetamide derivatives as CDK12/13 inhibitors | 奥里吉恩肿瘤学有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118459485-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-01 | — | — | US | disclosed |
| US-20240150358-A1 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. | 2024-05-09 | — | — | US | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| US-6881733-B1 | Serotonergic benzofurans | ELI LILLY AND COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1204660-B1 | SEROTONERGIC BENZOTHIOPHENES | LILLY CO ELI (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1204659-B1 | SEROTONERGIC BENZOFURANS | LILLY CO ELI (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1204659-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204660-A1 | SEROTONERGIC BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001009126-A1 | SEROTONERGIC BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009122-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000692-A1 | Substituted N-(Pyridin-2-yl)Acetamide Derivatives as CDK12/13 Inhibitors | CDK1, CDK12, CDK11A | NR1H2 891/4885NR1H3 880/4885HSD11B1 835/4885 |
| US-20240254138-A1 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CDK2, CCNK | NR1H2 2913/4885NR1H3 2632/4885HSD11B1 2690/4885 |
| US-20240150358-A1 | PURINES AND METHODS OF THEIR USE | PNP, NUDT1, HPRT1 | NR1H2 3362/4885NR1H3 3296/4885HSD11B1 4366/4885 |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | NR1H2 77/4885NR1H3 118/4885HSD11B1 128/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | NR1H2 4660/4885NR1H3 4634/4885HSD11B1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.